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•	 Phase II Trial of 
Carboplatin, Paclitaxel, 
Cetuximab, and 
Bevacizumab Followed 
by Cetuximab 
and Bevacizumab 
in Advanced 
Nonsquamous Non–
Small-Cell Lung Cancer: 
SWOG 0536
Whether combining cetuximab and bevacizumab with carboplatin 
and paclitaxel will benefit chemotherapy-naive patients with advanced 
nonsquamous non–small-cell lung cancer was investigated in this 
phase II study. Patients underwent six cycles of the treatment and 
were then given maintenance cetuximab and bevacizumab until  
IN THIS ISSUE
The metastatic development in the central nervous system (CNS) 
has been recognized as an emerging complication in non–small-cell 
lung cancer (NSCLC) patients with anaplastic lymphoma kinase 
(ALK) gene rearrangements receiving the ALK inhibitor crizotinib 
treatment. In this report, Gainor and colleagues presented a series 
of ALK-positive patients with two distinct types of 
metastatic involvement of the CNS: intramedullary 
spinal cord metastasis (ISCM) and leptomeningeal 
carcinomatosis (LC). It is the first report of ISCM in a 
patient with ALK-positive NSCLC. From a retrospective 
chart review of 96 ALK-positive patients, the authors 
identified ISCM in 4.17% of them and LC in 5.21%. 
These patients with CNS complications were previously 
treated or still undergoing treatment with crizotinib 
at the time of diagnosis. The time from diagnosis of 
NSCLC to development of ISCM (> 15 months) and 
LC (≥ 9 months) indicated that these are potentially 
late complications. Optimal treatments for patients with 
ISCM and LC have not yet been defined. The authors 
recommend clinicians to use neuroimaging in ALK-
positive patients presenting with neurologic symptoms. 
This report also underscores the need to develop 
next-generation ALK inhibitors with enhanced CNS 
penetration and antitumor activity. (p. 1570)
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disease progression. The primary endpoint was safety  
(i.e., frequency and severity of hemorrhagic toxicities). The 
secondary endpoints were response rate, progression-free 
survival, overall survival, and toxicity. Association between 
clinical outcomes and biomarkers such as EGFR and KRAS 
mutation status, and EGFR protein H score were also 
explored but no statistically significant associations were 
observed, except for circulating cytokine-angiogenesis 
factors. In 110 patients enrolled, 2% had grade 4 or higher 
hemorrhage and there were four treatment-related deaths 
including hemorrhage and infection. With a median 
progression-free survival of 7 months, median overall 
survival of 15 months, response rate of 56%, and 77% of 
overall disease control rate, the regimen was demonstrated 
to be safe, effective, and feasible as a first-line treatment 
for this study population. A phase III trial for further 
assessment is underway. (p. 1519)
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•	 The IASLC/ITMIG Thymic 
Malignancies Staging 
Project: Development of 
a Stage Classification for 
Thymic Malignancies
for International Cancer Control 8th edition of stage 
classification system for thymic malignancies. This 
article outlines the structure of this project and the 
plans designed to achieve the goal. To foster global 
collaboration in thymic malignancies, retrospective and 
prospective databases were created, with over 10,000 
cases worldwide being assembled for analysis. Careful 
evaluation of characteristics, guiding principles, and 
the process for the development of a thymic stage 
classification system were discussed. The development 
of a prognostic model for thymic malignancies to guide 
treatment was also proposed. (p. 1467)
treat and as having poorer QoL and higher symptom 
reports versus other solid tumor patients. To further 
assess the possibility of nihilism and perception bias, 
the persistence of the disease-specific differences was 
observed after other explanatory covariates (stage, 
performance status, and patient reports) were included. 
For lung cancer patients, lower QoL was perceived with 
an odds ratio of 3.6 (p < 0.0001) whereas weight gain/
loss difficulties with an odds ratio of 3.2 (p = 0.0004). 
To conclude, clinicians were more pessimistic about the 
well-being of their lung cancer patients versus others 
with solid tumors. Perception differences of patient 
QoL and weight difficulties persisted after adjusting for 
covariates. The study suggested that subtle and possible 
physician nihilism and perception bias could affect 
treatment options and disease management; further 
studies are required to confirm these findings and gain 
better understanding. (p. 1474)
Photo credit: Mike Blackburn (http://www.flickr.com/
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•	 Clinician Perceptions 
of Care Difficulty, 
Quality of Life, and 
Symptom Reports for 
Lung Cancer Patients: 
An Analysis from ECOG 
E2Z02 (Symptom 
Outcomes and Practice 
Patterns)
To investigate the potential clinician perception differences for 
their lung cancer patients compared with other patients having 
breast, prostate, and colon cancer, the authors specifically 
evaluated care difficulty, quality of life (QoL), and symptom 
reports from clinicians’ responses. Analysis from the Eastern 
Cooperative Oncology Group Symptom Outcomes and Practice 
Patterns study (E2Z02) was reported, which included clinician 
ratings of 3106 patients with solid tumors. The findings revealed 
that clinicians perceived lung cancer patients as more difficult to 
The International Association for the Study of Lung Cancer and 
the International Thymic Malignancies Interest Group joined effort 
in forming a Thymic Malignancies Domain of the Staging and 
Prognostic Factors Committee, responsible for the development 
of proposals for the American Joint Committee on Cancer/Union 
RESEARCH WATCH
•	 ACRIN 6668/RTOG 0235 
Trial: Prognostic value of 
[18F]Fluorodeoxyglucose 
Positron Emission 
Tomography in Patients 
with Locally Advanced 
Non–Small-Cell Lung 
Cancer Receiving 
Chemoradiation Therapy
Machtay et al. evaluated the association of standardized 
uptake value (SUV) on posttreatment [18F]
fluorodeoxyglucose positron emission tomography 
with survival of stage III non–small-cell lung 
cancer patients. Patients did not receive surgery but 
underwent conventional concurrent platinum-based 
chemoradiotherapy. The primary endpoint was peak 
SUV (SUV
peak
). The study population of 250 patients 
had a 2-year survival rate of 42.5%. No association 
with survival was found with pretreatment SUV
peak
 and 
SUV
max
 (mean, 10.3 and 13.1, respectively) whereas a 
higher posttreatment tumor SUV (SUV
peak
 or SUV
max
) is 
linked to poorer survival in these patients (hazard ratio: 
1.087; p = 0.020). In exploratory analyses, a link to 
survival was found when a SUV
peak
 cutoff of 5.0  
(p = 0.041) or 7.0 (p < 0.001) was used. Similar findings 
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were found by using SUV
max
. The study suggests that 
there is a prognostic value of SUV in these patients 
although more studies are warranted to determine a clear 
cutoff value for its use in routine clinics.
Machtay M, Duan F, Siegel BA, et al. Prediction of 
survival by [18F]fluorodeoxyglucose positron emission 
tomography in patients with locally advanced non-small-
cell lung cancer undergoing definitive chemoradiation 
therapy: results of the ACRIN 6668/RTOG 0235 Trial.  
J Clin Oncol, doi:10.1200/jco.2012.47.5947 (2013).
•	 ATLAS: Maintenance 
Bevacizumab with or 
without Erlotinib for 
Advanced Non–Small-
Cell Lung Cancer After 
First-Line Bevacizumab 
Treatment
This randomized, double-blind, placebo-controlled, 
phase IIIb study aimed to determine whether adding 
erlotinib to bevacizumab maintenance therapy after 
first-line chemotherapy regimen with bevacizumab 
would benefit patients with advanced non–small-cell 
lung cancer (stage IIIB with malignant pleural effusion, 
stage IV, or recurrent). In the study population of 743 
patients randomized to receive bevacizumab with or 
without erlotinib postchemotherapy, addition of erlotinib 
to bevacizumab significantly improved progression-
free survival: 3.7 months with bevacizumab/placebo 
versus 4.8 months with bevacizumab/erlotinib (hazard 
ratio, 0.71; p < 0.001). But no significant improvement 
was observed in overall survival: 13.3 versus 14.4 
months, respectively (hazard ratio, 0.92; p = 0.5341). 
Increased toxicity was also found in the bevacizumab/
erlotinib arm. The results of this study did not provide 
sufficient evidence to support the addition of erlotinib to 
bevacizumab maintenance as a new standard of care.
Johnson BE, Kabbinavar F, Fehrenbacher L, et al. 
ATLAS: randomized, double-blind, placebo-controlled, 
phase IIIB trial comparing bevacizumab therapy with 
or without erlotinib, after completion of chemotherapy, 
with bevacizumab for first-line treatment of advanced 
non-small-cell lung cancer. J Clin Oncol, doi:10.1200/
jco.2012.47.3983 (2013).
•	 Randomized Phase II 
Trial of Onartuzumab 
in Combination with 
Erlotinib in Patients 
with Advanced  
Non–Small-Cell Lung 
Cancer Based on MET 
Status
The authors evaluated the clinical benefit of inhibiting 
MET/epidermal growth factor receptor in patients with 
non–small-cell lung cancer, in which up-regulated 
hepatocyte growth factor/MET activity has been shown 
to link to poor prognosis and resistance to anti–epidermal 
growth factor receptor therapy. Onartuzumab/erlotinib or 
placebo/erlotinib was randomly assigned to patients with 
recurrent non–small-cell lung cancer. MET status was 
determined by immunohistochemistry on tumor tissues. No 
improvement of progression-free survival (PFS) and overall 
survival (OS) was observed in the intent-to-treat population 
(n = 137, hazard ratio [HR], 1.09; p = 0.69; OS HR, 0.80; 
p = 0.34) whereas prolonged PFS and OS were found in 
MET-positive patients receiving onartuzumab/erlotinib (PFS 
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HR, 0.53; p = 0.04; OS HR, 0.37; p= 0.002). Onartuzumab/
erlotinib-treated MET-negative patients had worse PFS 
(HR, 1.82; p = 0.05) and OS (HR, 1.78; p = 0.16). Worse 
PFS (HR, 1.71; p = 0.06) and OS (HR, 2.61; p = 0.004) 
were found in MET-positive control versus MET-negative 
control patients. Taken together, the findings demonstrated 
that MET-positive patients receiving onartuzumab/erlotinib 
showed better clinical outcomes, and underscore the 
importance of MET status testing in optimizing treatment 
outcomes. A phase III study is ongoing.
Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized 
phase II Trial of onartuzumab in combination with erlotinib 
in patients with advanced non-small-cell lung cancer. J Clin 
Oncol, doi:10.1200/jco.2012.47.4189 (2013).
NEWS IN BRIEF
•	 European Cancer Congress 
(ECC) 2013: New Anti–
PD-L1 Antibody Shows 
Efficacy in Metastatic 
NSCLC Patients Including 
Smokers
treatment to date, with 138 patients evaluable for safety 
and efficacy, and 81% of current or former smokers. 
Objective response rate (ORR) of 23% was achieved in 
this cohort; the 24-week progression-free survival rate 
of 44% was observed in patients with squamous tumors 
and 46% in nonsquamous tumors. Smoking status and 
PD-L1 expression on immunohistochemistry were 
predictive of response. Higher level of PD-L1 expression 
was associated with increased ORR and decreased 
progressive disease. Former smokers showed a 26% ORR 
whereas never-smokers demonstrated a 10% ORR. The 
treatment seemed to be well tolerated, with generally 
grade 1 and 2 adverse events.
•	 American Society of 
Therapeutic Radiology 
Oncology (ASTRO) 2013: 
PET Could Identify High-
Risk Early Lung Cancer
after stereotactic body radiation therapy (SBRT). Of 
the 171 patients with T1-3 N0M0 non–small-cell lung 
cancer treated with SBRT, median survival was 14.65 
months at a median follow-up of 14 months. The 
absolute reduction in SUV
max
, the maximum change 
in standardized uptake value, was one of the four 
independent predictors of any SBRT failure (hazard 
ratio, 0.856, p=0.005). Other predictors were age, tumor 
size, and squamous-cell histology. A lower pretreatment 
SUV was associated with prolonged overall survival 
(hazard ratio, 1.132, p=0.001). These findings, if 
confirmed in prospective studies with standardized 
positron emission tomography protocol, could stratify 
low- and high-risk patients for clinical decision making.
Photo source: National Institutes of Health
A phase I trial study evaluating the novel anti–PD-L1 antibody, 
MPDL3280A, showed promising results in the treatment of patients 
with metastatic non–small-cell lung cancer, including smokers and 
nonsmokers, with squamous and adenoma tumors. The non–small-
cell lung cancer cohort is the largest group under anti–PD-L1 
At the American Society of Therapeutic Radiology Oncology 
meeting, Mancini and colleagues presented the findings from 
their retrospective study on the use of positron emission 
tomography imaging to identify prognostic markers for patients 
with inoperable, early non–small-cell lung cancer before and 
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cancer (55) and prostate cancer (40) from propensity-
matched controls. Up to sixfold higher levels of serum 
free fatty acids and metabolites were observed in lung 
cancer patients versus controls (areas under the receiver 
operating characteristics curve: 0.71–0.82, p<0.001). 
Levels of these markers dropped by three to 10 times 
within 24 hours after lung tumor resections. Dr. Sessler 
suggested that this test, rather than widespread screening, 
could potentially be useful in high-risk patients and be 
used in parallel with other tests, for example, computed 
tomography screening. It is also considered most useful 
in monitoring recurrence postresection. A prospective 
trial will be underway to validate the blood test as a 
biomarker for recurrence.
Photo source: CDC
•	 Outdoor Air Pollution a 
Leading Environmental 
Cause of Cancer Deaths 
(http://ecancer.org/
news/4616-outdoor-
air-pollution-a-leading-
environmental-cause-
of-cancer-deaths.php)
Outdoor air pollution has been classified as carcinogenic 
by the International Agency for Research on Cancer 
of WHO. More than 1000 scientific literature articles 
on analysis of carcinogenicity of air pollutants across 
Europe, Asia, and North and South America were 
reviewed. Particulate matter and transportation-related 
pollution were among the air pollutants analyzed. Strong 
evidence from the review demonstrated significantly 
increased risk of developing lung cancer in people 
exposed to outdoor air pollution. An association of 
exposure to air pollution with increased risk of bladder 
cancer was also observed. This is the first time that 
experts have classified outdoor air pollution as a cause 
of cancer, and it should serve as a strong message for 
prompt measures in reducing air pollution worldwide.
•	 Anesthesiology™ 
2013 Annual Meeting: 
Simple Blood Test May 
Diagnose Lung and 
Other Cancers
According to the data presented by Daniel I. Sessler from The 
Cleveland Clinic, a blood test that measures serum free fatty 
acids and their metabolites could differentiate patients with lung 
